DK3630177T5 - Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling - Google Patents

Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling Download PDF

Info

Publication number
DK3630177T5
DK3630177T5 DK18728153.0T DK18728153T DK3630177T5 DK 3630177 T5 DK3630177 T5 DK 3630177T5 DK 18728153 T DK18728153 T DK 18728153T DK 3630177 T5 DK3630177 T5 DK 3630177T5
Authority
DK
Denmark
Prior art keywords
antibody
combination therapy
treatment paradigm
venetoclax combination
venetoclax
Prior art date
Application number
DK18728153.0T
Other languages
English (en)
Other versions
DK3630177T3 (da
Inventor
Peter Kelemen
Michael Schwarz
Mark Winderlich
Steffen Heeger
Dominika Weinelt
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of DK3630177T3 publication Critical patent/DK3630177T3/da
Application granted granted Critical
Publication of DK3630177T5 publication Critical patent/DK3630177T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK18728153.0T 2017-05-31 2018-05-30 Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling DK3630177T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173712 2017-05-31
PCT/EP2018/064229 WO2018220040A1 (en) 2017-05-31 2018-05-30 Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment

Publications (2)

Publication Number Publication Date
DK3630177T3 DK3630177T3 (da) 2023-10-16
DK3630177T5 true DK3630177T5 (da) 2024-09-02

Family

ID=59070416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18728153.0T DK3630177T5 (da) 2017-05-31 2018-05-30 Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling

Country Status (27)

Country Link
US (1) US20250186460A1 (da)
EP (2) EP3630177B1 (da)
JP (2) JP7399713B2 (da)
KR (2) KR20200010472A (da)
CN (1) CN110678201A (da)
AU (2) AU2018276384B2 (da)
BR (1) BR112019025034A2 (da)
CA (1) CA3062400A1 (da)
CY (1) CY1126559T1 (da)
DK (1) DK3630177T5 (da)
ES (1) ES2961940T3 (da)
FI (1) FI3630177T3 (da)
HR (1) HRP20231229T1 (da)
HU (1) HUE063119T2 (da)
IL (2) IL270855B2 (da)
LT (1) LT3630177T (da)
MA (1) MA48751B1 (da)
MD (1) MD3630177T2 (da)
MX (2) MX2019014330A (da)
PL (1) PL3630177T3 (da)
PT (1) PT3630177T (da)
RS (1) RS64746B1 (da)
SG (1) SG11201909715VA (da)
SI (1) SI3630177T1 (da)
SM (1) SMT202300338T1 (da)
WO (1) WO2018220040A1 (da)
ZA (1) ZA201907369B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2022115120A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
US20220241411A1 (en) * 2020-11-30 2022-08-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG10201606785UA (en) 2011-08-16 2016-10-28 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
CA2841738C (en) 2011-08-16 2022-12-06 Morphosys Ag Combination therapy with an anti-cd19 antibody and a purine analog
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
WO2018078123A1 (en) * 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Also Published As

Publication number Publication date
AU2018276384B2 (en) 2025-02-13
RU2019139552A3 (da) 2021-09-22
RU2019139552A (ru) 2021-07-01
AU2025203436A1 (en) 2025-06-05
IL270855A (en) 2020-01-30
MX2019014330A (es) 2020-02-05
ES2961940T3 (es) 2024-03-14
LT3630177T (lt) 2023-10-25
JP2020521777A (ja) 2020-07-27
CY1126559T1 (el) 2026-02-25
HUE063119T2 (hu) 2024-01-28
IL297461A (en) 2022-12-01
MA48751A (fr) 2020-04-08
PT3630177T (pt) 2023-11-10
WO2018220040A1 (en) 2018-12-06
EP4268900A2 (en) 2023-11-01
BR112019025034A2 (pt) 2020-06-30
IL297461B2 (en) 2024-09-01
EP4268900A3 (en) 2024-03-06
AU2018276384A1 (en) 2019-11-07
DK3630177T3 (da) 2023-10-16
MA48751B1 (fr) 2023-11-30
PL3630177T3 (pl) 2024-04-08
SI3630177T1 (sl) 2023-12-29
KR20200010472A (ko) 2020-01-30
IL270855B2 (en) 2023-03-01
FI3630177T3 (fi) 2023-10-18
KR20240117655A (ko) 2024-08-01
MX2023013228A (es) 2024-04-16
JP2024028865A (ja) 2024-03-05
ZA201907369B (en) 2024-04-24
JP7399713B2 (ja) 2023-12-18
IL270855B (en) 2022-11-01
IL297461B1 (en) 2024-05-01
CN110678201A (zh) 2020-01-10
SMT202300338T1 (it) 2023-11-13
RS64746B1 (sr) 2023-11-30
US20250186460A1 (en) 2025-06-12
HRP20231229T1 (hr) 2024-02-02
EP3630177A1 (en) 2020-04-08
EP3630177B1 (en) 2023-08-09
MD3630177T2 (ro) 2024-01-31
CA3062400A1 (en) 2018-12-06
SG11201909715VA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
DK3630177T3 (da) Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling
DK3245938T3 (da) Anordning og fremgangsmåde til at identificere endoskoptype og tilvejebringe skræddersyet efterbehandling
DK3802014T3 (da) Styreindretning og fremgangsmåde til emneverifikation
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3455259T5 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK4008359T3 (da) Psma-ligander til billeddannelse og endoradioterapi
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3478723T3 (da) Pd l1 specifikke antistoffer og metoder til anvendelse heraf
DK3294770T3 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3692009T3 (da) Biocementationsfremgangsmåde og system
DK4241685T3 (da) Medicinsk system og fremgangsmåde til fremstilling deraf
IL268874A (en) Peptides and methods for the treatment of diabetes
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
IL282478A (en) Materials and methods for treating cancer
DK3458650T3 (da) Fremgangsmåde til desinficering og vandhaneforbindelsesarrangement dertil
DK3431679T3 (da) Panelbæresystem og fremgangsmåde
DK3841066T3 (da) Afsaltningssystem og fremgangsmåde